Smart Development

Návrat žluté zimnice

May 16, 2016 Melvin Sanicas

SEATTLE – Ještě před tím, než vůbec z našich myslí mohly začít mizet hrůzy z posledního vzplanutí eboly v západní Africe, objevil se virus zika v podobě hlavního celosvětového zdravotního rizika a v současnosti zaměstnává výzkumníky a lékaře v Jižní Americe, Střední Americe a v Karibiku. Rychle však roste počet obětí dalšího viru: žluté zimnice.

Angola v jihozápadní Africe čelí závažné epidemii žluté zimnice – první za posledních 30 let. Od doby, co se virus minulý prosinec objevil v Luandě, hlavním a nejlidnatějším městě Angoly, zabil 293 lidí a nakazil odhadovaných 2 267. Virus se nyní rozšířil do 6 z 18 provincií země. Cestovatelé zanesli virus do Číny, Demokratické republiky Kongo a Keni. Namibie a Zambie jsou ve stavu pohotovosti.

Virus žluté zimnice je přenášen Aedes aegypti – stejným komárem, který šíří virus zika. Symptomy zahrnují horečku, svalovou bolest, bolesti hlavy, nevolnost zvracení a únavu. Nejméně polovina neléčených pacientů s těžkou formou zimnice zemře během 10-14 dnů.

To continue reading, register now.

Subscribe now for unlimited access to everything PS has to offer.

As a registered user, you can enjoy more PS content every month – for free.

Already have an account? Log in

PS Events: What Economics is Missing

Our latest event, What Economics is Missing, is now live.

Click the link below for opening remarks from Dani Rodrik, followed by a discussion among Ashwini Deshpande, Raquel Fernández, Minouche Shafik, and Vera Songwe on how to achieve inclusivity in economics.

Watch Now

new comment has been posted. new comments have been posted.

0 Comments on this paragraph, 8 Comments on this article

Juan Miguel Martinez Jun 22, 2016

WHO details $72 million yellow fever response plan. The WHO will work with partners to meet those objectives in outbreak countries, nations that border the outbreak or where yellow fever is endemic, and other countries at risk because of international travel and trade and the presence Aedes mosquitoes. http://www.who.int/emergencies/yellow-fever/response/en/
A new reply to this comment has been posted.
Melvin Sanicas Jun 17, 2016

Update: Since early December, the Ministry of Health has reported a total of 3137 suspected cases of which 847 are laboratory confirmed. The total number of reported deaths is 345, of which 112 are reported among confirmed cases. Read more at http://outbreaknewstoday.com/yellow-fever-in-africa-case-and-country-update-lower-doses-of-yellow-fever-vaccine-15869/
A new reply to this comment has been posted.
Melissa Butler Jun 9, 2016

I can see why lowering the dosage would be helpful to try and battle against the issue of a tight supply but as you say, but that may not even be enough if this continues to spread quickly and further than before!
- Juan Miguel Martinez Jun 10, 2016
  
  Experts at WHO are currently working on a plan to advise member states to use 1/5 of the normal dose per person. Unrelated outbreaks in Uganda and Peru are putting further pressure on the vaccine supplies.
  A new reply to this comment has been posted.
A new reply to this comment has been posted.
Kristina Laskova May 21, 2016

I really like this article and completely agree with the author. Everything is very well said and written. Yellow Fever is definitely back, I have heard many cases which happened in recent past.
A new reply to this comment has been posted.
Steve Hurst May 17, 2016

What cost less than 1USD is not the same vaccine package that now cost 70x ref to MSF list. What is needed is a direct comparison. The idea this unit price data is not available in a multi billion USD activity dealing with millions of patients is a bit thin. If there is also a huge variation in unit price dependent on location then purchase protocols need attention. Diluting vaccine doses has no impact on the labour cost of a programme of vaccination and it is not made clear what the current unit cost of yellow fever vaccination as it is bundled with other vaccines. Furthermore what is not presented is the unit cost required to be affordable
- Steve Hurst May 20, 2016
  
  @Juan
  
  Thank you for the calrification. There still appears to be a lack of data in a multi billion operation. Further, what was the efficacy of the 1USD option
  A new reply to this comment has been posted.
- Juan Miguel Martinez May 17, 2016
  
  The vaccine that costs less than 1 USD is not the same vaccine that now costs 70x but the fact is that the cost of the vaccine is a hurdle especially in developing countries. Diluting vaccine doses may not have an impact on the labor cost of a programme but it does allow more people to be vaccinated.
  A new reply to this comment has been posted.
A new reply to this comment has been posted.

https://prosyn.org/NWYsSkKcs

Email required

Password required Remember me?

Facebook

Microsoft

Twitter

Návrat žluté zimnice

PS Events: What Economics is Missing

New Comment

Contact us

Log in/Register

Návrat žluté zimnice

PS Events: What Economics is Missing

Edit Newsletter Preferences

Set up Notification